Oaktree SPAC draws trader attention after 5% filing
Oaktree Acquisition Corp. III Life Sciences’ Class A shares closed unchanged at $10.64 on Friday, with only 10 shares traded. Fort Baker Capital Management disclosed a 5.1% stake, days after the SPAC reported no merger target and an Oct. 25 deadline. First-quarter net income fell to $1.39 million as trust interest declined. Cash held in trust totaled $203.4 million at March 31.